Robert Billingsley
Psychiatry · Fayetteville, ARNPI 1790846947
Payments from drug & device makers
Across 943 payments — averaging $6308.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.2M
- Sunovion Pharmaceuticals Inc.$1M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$718K
- Vanda Pharmaceuticals Inc.$607K
- AbbVie$548K
- Teva Pharmaceuticals USA, Inc.$532K
- plus $1.3M from 15 others
Across 7 payments — averaging $227.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
- Eli Lilly$224
What the payments were for
- Travel & lodging$1,82874%
- Food & beverage$63326%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 283 | $1,209,831 |
| Sunovion Pharmaceuticals Inc. | 156 | $1,001,974 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $718,287 |
| Vanda Pharmaceuticals Inc. | 13 | $606,851 |
| AbbVie(2 entities) | 153 | $547,814 |
| Teva Pharmaceuticals USA, Inc. | 41 | $532,415 |
| Sumitomo Pharma America, Inc. | 80 | $379,969 |
| Sage Therapeutics, LLC | 47 | $330,710 |
| Merck | 8 | $269,772 |
| Genentech, Inc. | 26 | $108,835 |
| Alkermes, Inc. | 20 | $57,653 |
| LEO Pharma AS | 11 | $39,317 |
| E.r. Squibb & Sons, L.L.C. | 6 | $35,147 |
| Janssen Research & Development, LLC | 17 | $34,008 |
| Boehringer Ingelheim | 4 | $21,653 |
| Roche TCRC, Inc. | 2 | $21,652 |
| Boehringer Ingelheim International GmbH | 47 | $15,134 |
| Hoffmann-la Roche Limited | 3 | $8,700 |
| Eisai Inc. | 5 | $5,970 |
| Neurocrine Biosciences, Inc. | 14 | $2,461 |
| Jazz Pharmaceuticals Inc. | 1 | $825 |
How this compares
$5,948,979 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clorazepate Dipotassium | 12 | $836 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $346 |
| Clonazepam | 31 | $217 |
| Amitriptyline Hcl | 17 | $127 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Fayetteville
- Angela ChapmanFayetteville$40K
- Jacquelyn Lange-HalleyFayetteville$8K
- Devin McDonaldFayetteville$6K
- Shefa RahmanFayetteville$4K
- Leslie SmithLittle Rock$7.9M
- Gintaras AukstuolisLittle Rock$6.6M
- Paul WylieLittle Rock$3.4M
- Robert WootenPine Bluff$945K
- Prasad PadalaNorth Little Rock$868K
- Tad TillemansLittle Rock$656K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.